We found the increased HTR2A on fibroblast in inflammatory joint is partly due to the decreased miRNAs targeting HTR2A carried by exosomes, which explore a new potential therapeutic target and effective therapeutic carriers for RA treatment. The gene discussed is HTR2A; the disease is rheumatoid arthritis.